Related references
Note: Only part of the references are listed.CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies
Yu Zhao et al.
CLINICAL CANCER RESEARCH (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Fludarabine and neurotoxicity in engineered T-cell therapy
Kate L. Lowe et al.
GENE THERAPY (2018)
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype
Saisai Li et al.
HUMAN GENE THERAPY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold
Alexey Teplyakov et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Jean-Marc Hoffmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Role of memory T cell subsets for adoptive immunotherapy
Dirk H. Busch et al.
SEMINARS IN IMMUNOLOGY (2016)
Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
Na An et al.
ONCOTARGET (2016)
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Vita Golubovskaya et al.
CANCERS (2016)
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
Tessa Gargett et al.
CYTOTHERAPY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Human effector T cells derived from central memory cells rather than CD8+T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy
Fenglin Wu et al.
CANCER LETTERS (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Christopher A. Klebanoff et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Paths to stemness: building the ultimate antitumour T cell
Luca Gattinoni et al.
NATURE REVIEWS CANCER (2012)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
Christian S. Hinrichs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adoptive transfer of effector CD8(+) T cells derived from central memory cells establishes persistent T cell memory in primates
Carolina Berger et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
